Patients in the anti-MRSA Ceph + DAP arm had a 59.9% (95% CI, 52.4%–67.4%) probability of having a better outcome than those in the OAR arm. Esp, anti-MRSA Ceph +DAP was associated with reduced mortality (aHR, 0.54 [95% CI, .34–.85]), confirmed after adjustment with IPTW analysis #idsky